Metastatic castration-resistant prostatic cancer

Clinical trials for Metastatic castration-resistant prostatic cancer explained in plain language.

Never miss a new study

Get alerted when new Metastatic castration-resistant prostatic cancer trials appear

Sign up with your email to follow new studies for Metastatic castration-resistant prostatic cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New Antibody-Drug conjugate takes aim at Hard-to-Treat prostate cancer

Disease control Recruiting now

This study tests a new drug called TD001 in men with a type of advanced prostate cancer that has stopped responding to hormone therapy. TD001 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly to prostate cancer cells that have a specific marker (…

Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATIC CANCER

Phase 1/2 • Sponsor: T.O.A.D. Oncology SA • Aim: Disease control

Last updated Jun 27, 2026 13:00 UTC

Metastatic castration-resistant prostatic cancer

Get alerted when new Metastatic castration-resistant prostatic cancer trials appear

New Antibody-Drug conjugate takes aim at Hard-to-Treat prostate cancer